Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| No NIH funding | Other Identifier | 10.11.23 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess risks of bleeding in those individuals receiving Novel Oral Anti-Coagulant (NOAC) medications, admitted to the hospital and require thoracentesis, chest tube or tunneled pleural catheter placement.
The research component of this study simply observes and documents the outcomes of these procedures. Patients will undergo an analysis of their pre-procedural hematocrit and this will be compared to their post-procedural (next day) hematocrit.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients taking NOAC's | Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement and are taking Novel Oral Anti-Coagulants (NOAC). |
| |
| patients not taking NOAC's | Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement who are not taking Novel Oral Anti-Coagulants (NOAC). |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Novel Oral Anti-Coagulants | Drug | Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Risk of bleeding | Reduced risk of bleeding in individuals receiving Novel Oral Anti-Coagulants as well as those that are in the control group will be assessed by having the patients undergo an analysis of their pre-procedural hematocrit which will be compared to their post procedural (next day) hematocrit | 2 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Adults who refuse to provide consent.
Not provided
Not provided
Not provided
Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kyle Bramley, MD | Yale University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yale New Haven Hospital | New Haven | Connecticut | 06510 | United States |
Not provided
| ID | Term |
|---|---|
| D010996 | Pleural Effusion |
| ID | Term |
|---|---|
| D010995 | Pleural Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C065145 | N(4)-oleylcytosine arabinoside |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided